Last year, researchers surveyed 13 eye clinics across country and found that only two out of every ten (17.6 per cent) of the surveyed children and teenagers with short-sightedness (myopia) wore ...
Clearside Biomedical (CLSD) announced that presentations on the Company’s lead clinical program, CLS-AX in neovascular age-related macular ...
Clearside Biomedical, Inc. announced on March 20, 2025, that it presented findings on its lead clinical program, CLS-AX, a suprachoroidal injectable suspension of axitinib, at the 2025 Wet AMD ...
Detailed price information for Clearside Biomedi (CLSD-Q) from The Globe and Mail including charting and trades.